On the development of personalized cancer vaccines

Hans-Georg Rammensee*

Department of Immunology, University of Tübingen, Tübingen, Germany

* Corresponding author, email: rammensee@uni-tuebingen.de

© 2018 Hans-Georg Rammensee; licensee Infinite Science Publishing

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cancer immunotherapy has experienced a breakthrough by the introduction of checkpoint inhibition with antibodies. Response appears to be correlated with mutation load; the majority of cancer patients are nonresponders, possibly due to absence of immunogenic neoepitopes. We analyze the entire detectable landscape of HLA ligands on tumor samples, consisting of 1000 through 5000 peptides per sample, and find dozens to hundreds of peptides in germline sequence with apparently tumor specific expression, based on the absence of these peptides on adjacent autologous benign tissue and absence on a large number of normal tissue samples from all organs and tissue types available for analysis. We have evidence that non-mutated HLA ligands with tumor specific expression should be efficient as targets for personalized antigen specific immunotherapy, in particular if used with an efficient adjuvant.